RACHEL GALLAGHER: Open Payments
NPI 1841851409 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,266 in 114 payments from 21 companies in 2025. Trend: 2023 $1,387 · 2024 $1,630 · 2025 $2,266
Food & beverage: $2,266
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $598 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $206 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $196 |
| Janssen Biotech, Inc. | 10 | $196 |
| Regeneron Healthcare Solutions, Inc. | 6 | $195 |
| Ardelyx, Inc. | 10 | $173 |
| Phathom Pharmaceuticals, Inc. | 7 | $115 |
| Braintree Laboratories, Inc. | 5 | $96 |
| PFIZER INC. | 4 | $76 |
| Lilly USA, LLC | 2 | $52 |
Products named: RINVOQ, DUPIXENT, XIFAXAN, TREMFYA, IBSRELA, ENTYVIO, VOQUEZNA, LINZESS.
Industry payments across IN — which companies pay providers there.
